Addition of pentoxifylline to pegylated interferon-alpha-2a and ribavirin improves sustained virological response to chronic hepatitis C virus: A randomized clinical trial

Annals of Hepatology

Volumn 12, Issue 2, 2013, Pages 248-255

  Jiménez Luévano, Miguel Ángel ^a   Lerma Díaz, José Manuel ^b,c   Hernández Flores, Georgina ^b   Jiménez Partida, Miguel Ángel ^d   Bravo Cuellar, Alejandro ^b,c  

^a Hospital Valentín Gómez Farías   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c UNIVERSITY OF GUADALAJARA   (Mexico)

^d Instituto de Genética Humana   (Mexico)

Author keywords

Chronic hepatitis C virus; Pegylated interferon alpha 2a; Pentoxifylline; Ribavirin; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; PENTOXIFYLLINE; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; HEPATITIS C ANTIBODY; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DYSPEPSIA; FEMALE; FEVER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOTHYROIDISM; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; VIRUS LOAD; VOMITING; WEIGHT REDUCTION; AGED; BLOOD; CHI SQUARE DISTRIBUTION; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; MEXICO; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MEXICO; MIDDLE AGED; PENTOXIFYLLINE; PILOT PROJECTS; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84885603331     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31363-8     Document Type: Article

References (21)

1. Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol 2008; 22: 991-1008.
2. Czepiel J, Biesiada G, Mach T. Viral hepatitis C. Pol Arch Med Wewn 2008; 118: 734-40.
3. García-Montalvo BM, Galguera-Colorado PL. Distribution of hepatitis C virus genotypes, risk factors and liver disease in patients from Yucatan, Mexico. Ann Hepatol 2008; 7: 345-9.
4. Feuerstadt P, Bunim AL, García H, Karlitz JJ, Massoumi H, Thosani AJ, Pellecchia A, et al. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology 2011; 51: 1137-43.
5. Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wedemeyer H, Sarrazin C, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009; 16: 75-90.
6. Simula MP, De Re V. Hepatitis C virus-induced oxidative stress and mitochondrial dysfunction: a focus on recent advances in proteomics. Proteomics Clin Appl 2010; 4: 782-93.
7. Olleros ML, Vesin D, Fotio AL, Santiago-Raber ML, Tauzin S, Szymkowski DE, García I. Soluble TNF, but not membrane TNF, is critical in LPS-induced hepatitis. J Hepatol 2010; 53: 1059-68.
8. Petrowsky H, Breitenstein S, Slankamenac K, Vetter D, Lehmann K, Heinrich S, DeOliveira ML, et al. Effects of pentoxifylline on liver regeneration: a double-blinded, randomized, controlled trial in 101 patients undergoing major liver resection. Ann Surg 2010; 252: 813-22.
9. Gupta SK, Johnson RM, Mather KJ, Clauss M, Rehman J, Saha C, Desta Z, et al. Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: a pilot study. AIDS 2010; 24: 1377-80.
10. Assem M, Yousri M. Impact of pentoxifylline and vitamin E on ribavirin-induced haemolytic anaemia in chronic hepatitis C patients: an Egyptian survey [Abstract]. Int J Hepatol 2011; 2011: 530949.
11. Hepgul G, Tanrikulu S, Unalp HR, Akguner T, Erbil Y, Olgac V, Ademoglu E. Preventive effect of pentoxifylline on acute radiation damage via antioxidant and anti-inflammatory pathways. Dig Dis Sci 2010; 55: 617-25.
12. Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis [Abstract]. BMJ 2011; 340: b5569.
13. Cross TJ, Calvaruso V, Foxton MR, Manousou P, Quaglia A, Grillo F, Dhillon AP, et al. A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation. J Viral Hepat 2010; 17: 640-9.
14. Kayadibi H, Gultepe M, Yasar B, Ince AT, Ozcan O, Ipcioglu OM, Kurdas OO, et al. Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: a surrogate marker to distinguish steatohepatitis from simple steatosis. Dig Dis Sci 2009; 54: 1764-71.
15. Okazaki K, Nishiyama Y, Saitou T, Shibata N, Yamamoto C, Oosaga J, Tanaka M, et al. Fundamental evaluation of HCV core antigen method comparison with Cobas Amplicor HCV monitor v2.0 (high range method). Rinsho Byori 2008; 56: 95-100.
16. Taye A, El-Moselhy MA, Hassan MK, Ibrahim HM, Mohammed AF. Hepatoprotective effect of pentoxifylline against Dgalactosamine-induced hepatotoxicity in rats. Ann Hepatol 2009; 8: 364-70.
17. Lee YM, Sutedja DS, Wai CT, Dan YY, Aung MO, Zhou L, Cheng CL, et al. A randomized controlled pilot study of pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008; 2: 196-201.
18. Mihaila RG, Nedelcu L, Fratila O, Rezi EC, Domnariu C, Deac M. Effects of lovastatin and pentoxifylline in nonalcoholic steatohepatitis. Hepatogastroenterology 2009; 56: 1117-21.
19. Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009: CD007339.
20. Jiménez-Luévano MA, Cortés-Nuño S, Rocha-López AN, Cervantes-Rodríguez MTG, Bravo-Cuéllar A, Franco-Topete R, Abascal-Medina CG. La pentoxifilina en la hepatitis fulminante: reporte de dos casos. Rev Biomed 2009: 20: 33-9.
21. Wystrychowski A, Wystrychowski W, Krol P, Obuchowicz E, Cierpka L, Wiecek A. Pentoxifylline augments fastinginduced nephroprotection in acute ischemic kidney injury in rats. Transplant Proc 2009; 41: 2992-3.